Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

Abstract Introduction Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life. This study evaluated the efficacy and safety of risankizumab, a humanized immunoglobuli...

Full description

Bibliographic Details
Main Authors: Alexa B. Kimball, Errol P. Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, Ziqian Geng, Tianyu Zhan, Izabella Messina, Falk G. Bechara
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Dermatology and Therapy
Subjects:
Hidradenitis suppurativa
Interleukin 23 inhibitor
Risankizumab
Online Access:https://doi.org/10.1007/s13555-023-00913-3

Internet

https://doi.org/10.1007/s13555-023-00913-3

Similar Items